Filing Flows

Filing Flows › 8-K events › BioXcel Therapeutics

BioXcel Therapeutics: completion of an acquisition or disposition of assets

Form 8-K filed Oct 30, 2026 · items 2.01, 5.02, 5.03

What the filing says

As previously disclosed, on August 27, 2026, BioXcel Therapeutics, Inc. (the “ Company ”) and its subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (together with the Company, the “ Debtors ”) filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code (the “

Read the filing on SEC EDGAR →

What usually followsAcross 2,671 8-Ks reporting Item 2.01 (completed acquisition or disposition) in our universe, the stock's median move the next session was +0.1% (typical size ±1.6%, up 52% of the time); over the following 21 sessions, +1.2%. Item 5.02: −0.1% next session across 39,174. Item 5.03: +0.1% next session across 5,869. Every item ranked →

What this kind of filing means

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

BioXcel Therapeutics at a glance

Latest quarterQ2 2026
Revenue$182K
Revenue Y/Y+52%
Operating marginn/m
IndustryPharmaceutical Preparations

BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year). The chart follows the revenue to costs, profit and cash.

BioXcel Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.